Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Capital Expenditures for 10 consecutive years, with $8040.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures fell 98.44% year-over-year to $8040.0, compared with a TTM value of $278130.0 through Sep 2025, down 76.27%, and an annual FY2024 reading of $1.7 million, up 1914.63% over the prior year.
  • Capital Expenditures was $8040.0 for Q3 2025 at Sunshine Biopharma, down from $160000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $974513.0 in Q2 2024 and bottomed at -$382363.0 in Q4 2023.
  • Average Capital Expenditures over 4 years is $165383.8, with a median of $82768.5 recorded in 2024.
  • The sharpest move saw Capital Expenditures crashed 297.11% in 2023, then skyrocketed 5266.46% in 2024.
  • Year by year, Capital Expenditures stood at $193982.0 in 2022, then plummeted by 297.11% to -$382363.0 in 2023, then soared by 126.83% to $102600.0 in 2024, then crashed by 92.16% to $8040.0 in 2025.
  • Business Quant data shows Capital Expenditures for SBFM at $8040.0 in Q3 2025, $160000.0 in Q2 2025, and $7490.0 in Q1 2025.